SCHEMBL10199290

SCHEMBL10199290

[C-]#[N+]c1cnc(Nc2ccc(C(C)C)c(-n3cnnn3)c2)nc1NC1CC(C)(C)NC(C)(C)C1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.39
CHEK1 O14757 1/20 0.33
FLT3 P36888 1/20 0.33
PRKCQ Q04759 1/20 0.31
BRD4 O60885 1/20 0.31
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
ALOX15 P16050 1/20 0.30
ALOX12 P18054 1/20 0.30
RAD52 P43351 1/20 0.30
GFER P55789 1/20 0.30
KMT2A Q03164 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL428025 0.88 PRKCQ (0.41) SYKCHEK1FLT3PRKCQ
SCHEMBL10199063 0.86 CSNK2A2 (0.34) SYKPRKCQ
SCHEMBL428862 0.86 SYK (0.39) SYKCHEK1FLT3PRKCQ
SCHEMBL433116 0.85 SYK (0.58) SYK
SCHEMBL10199027 0.82 SYK (0.36) SYKCHEK1FLT3PRKCQ
SCHEMBL10199108 0.82 SYK (0.38) SYKPRKCQ
SCHEMBL3495034 0.79 PRKCQ (0.45) SYKCHEK1FLT3PRKCQMEN1
SCHEMBL3493381 0.78 PRKCQ (0.44) SYKCHEK1FLT3PRKCQMEN1
SCHEMBL10198992 0.77 CSNK2A2 (0.35) SYKPRKCQ
SCHEMBL3494407 0.76 SYK (0.40) SYKCHEK1FLT3PRKCQMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181222-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-11-10 US disclosed
US-20140329842-A1 Protein Kinase C Inhibitors and Uses Thereof RIGEL PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-8710223-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2014-04-29 US disclosed
US-20120022092-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329842-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB SYK 600/4885CHEK1 328/4885FLT3 1016/4885
US-20120022092-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB SYK 600/4885CHEK1 328/4885FLT3 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.